Not all sodium-glucose cotransporter 2 inhibitors are created equal

SGLT2 inhibitor class of medications favourably affects risk for cardiovascular outcomes in patients with type 2 diabetes, despite some heterogeneity.
SGLT2 inhibitor class of medications favourably affects risk for cardiovascular outcomes in patients with type 2 diabetes, despite some heterogeneity.